Terapeutic vaccine as immunotherapy for hepatitis B and D
| Reference number | |
| Coordinator | Svenska Vacinfabriken Produktion AB - Svenska Vaccinfabriken Produktion AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | March 2019 - November 2019 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 1 spring 2019 |
Important results from the project
Svenska Vaccinfabriken Produktion AB has strengthen its patent portfolio and thereby increase the value of the intangible assets. Patent for therapeutic vaccine for the treatment of hepatitis B and D and to enable cure and protection against liver cancer. This has been done through broadened content in existing patents. We have also prepared a patent application for a candidate for the treatment of liver cancer. All in all, this has strengthened the company´s patent situation and breadth in our development portfolio as part of the global sustainability goals of eradicating hepatitis
Expected long term effects
Patent applications and validation of patents have been made in accordance with expected outcomes. This in turn has increased the company´s value of the intangible assets and the opportunity for external funding and continued development of the project clearly increased.
Approach and implementation
In close collaboration between researchers, companies and patent lawyers, we have generated data and content for strong patent improvements and through new research generated data for new applications. Close dialogue between the parties has been important in order to succeed.